Trial Profile
A Retrospective cohort study to evaluate the risk of febrile neutropenia associated with the early discontinuation of pegfilgrastim in patients who had received chemotherapy regimens for solid cancers or non-Hodgkin's lymphoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Apr 2017
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Chemotherapy induced febrile neutropenia
- Focus Adverse reactions; Therapeutic Use
- 06 Apr 2017 New trial record